“As we prepare to announce the 12-month results from the MASTER trial in October, we continue to put in place the appropriate infrastructure to be able to meet the anticipated increase in demand for our lifesaving stent technology.”
Embolic protection stent developer, InspireMD, Inc. has completed the first phase of a manufacturing consolidation that the Company believes will improve its long term gross margins. At the same time the company has said it will use service and distribution company Healthlink Europe, to provide logistical and customer support for its commercial operations and clinical activities across the continent.
We’ve covered InspireMD and its clever MGuard Embolic Protection Stent (EPS) quite extensively on our pages. To remind you, MGuard EPS is a conventional-looking stent with the additional feature of possessing an integrated micro net mesh that prevents the unstable arterial plaque and thrombus (clots) that caused the heart attack blockage from breaking off. It works in somewhat the same way as those nets that cover the inside of tunnels to stop rocks falling.
InspireMD has bases in Tel Aviv and Boston, and it is the Israeli end of the operation that is being “consolidated”, which usually means streamlined, which usually means some fat has been cut out.
On the European end of the business, Inspire MD clearly sees the advantage of devolving physical distribution of its products to Healthlink, which will provide InspireMD with customer service centre capabilities for handling inquiries from hospitals and distributors. Healthlink will handle all inventory controls, warehousing, shipping, and invoicing and receivables management for customers worldwide on behalf of InspireMD.
Both measures could be shrugged off as normal, good business practice, but in reality, combined with a raft of clinical studies and optimistic noises it seems the company is preparing itself for a major assault on the European market.
Alan Milinazzo, President and CEO of InspireMD, commented, “We have successfully completed the first stage of our manufacturing strategy through the consolidation of our Israeli manufacturing facilities. Over time, we believe that this will reduce our operating costs by streamlining our manufacturing operations.”
“As we prepare to announce the 12-month results from the MASTER trial in October, we continue to put in place the appropriate infrastructure to be able to meet the anticipated increase in demand for our lifesaving stent technology. The agreement with Healthlink Europe is intended to support both current commercial activities as well as ongoing clinical trials, and should provide us instant access to world-class customer logistics to support all of our customers through a single partner,” concluded Mr. Milinazzo.
Source: InspireMD, Inc.